Ronald Krauss, Senior Scientist and Director of Atherosclerosis Research at Children’s Hospital Oakland Research Institute, cautions that physicians should not rely exclusively on LDL cholesterol for assessing or managing risk.He discusses how the direct measurement of lipoprotein particles, using ion mobility analysis, and an assessment of a patient’s overall lipoprotein particle profile provide a basis for more accurate assessment of risk and monitoring of therapy.Patrick James, Senior Medical Director, Quest Diagnostics, discusses how genetic testing provides physicians with valuable information to help identify patients with Hereditary Breast and Ovarian Cancer (HBOC) syndrome and provides a basis for potentially lifesaving interventions.He reviews how technology has evolved to offer physicians different testing options and more precise information regarding their patients’ potential risk.Cesar Molina, Heart and Vascular Associates, Mountain View, California, discusses the significance of residual risk and outlines how a more comprehensive approach to patient management, beyond a single focus on reducing LDL-C, can reduce clinical events in at-risk populations.Advanced Lipid Testing: Enabling a More Accurate Assessment of Cardiovascular Disease Risk Dr.Cardio IQ in Primary Care: Uncovering the Hidden High-Risk Patient Dr.John Corso presents two cardiovascular patient case studies that highlight the value of uncovering residual risk in the management of cardiovascular disease.
BRCA Mutation Testing—Identifying Risk for Hereditary Breast and Ovarian Cancer Dr.
Health Trends™ – H1N1 Influenza Quest Diagnostics is the first independent lab in the US to perform H1N1 laboratory testing and provides two H1N1 test kits that the FDA has authorized for emergency use by other qualified molecular laboratories. The proportion of test results deemed to represent good diabetes control increased from 36% in early 2001 to a high of 56% in late 2005.
Women's Health A Quest Diagnostics Health Trends study finds that many pregnant women are not screened for two common sexually transmitted diseases.
Douglas Jacoby helps participants understand when to consider advanced risk assessment and blood tests, what assessments to use, and the future therapeutic choices beyond statins.
Review of Clinical Research and the Effective Use of Omega -3 &-6 Fatty Acids in Patient Management Robert Superko, MD, and Michael Caulfield, Ph D, discuss the current clinical research on the use of omega-3 and omega-6 supplementation and their link to decreased risk of cardiovascular events, including sudden cardiac death.
Advanced Insights into Residual Cardiovascular Risk—Another Perspective Dr.